• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Aadi Bioscience Inc.

    3/11/25 7:22:10 PM ET
    $AADI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AADI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Aadi Bioscience, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    00032Q104

    (CUSIP Number)


    03/04/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00032Q104


    1Names of Reporting Persons

    SUVRETTA CAPITAL MANAGEMENT, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,727,510.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,727,510.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,727,510.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    00032Q104


    1Names of Reporting Persons

    Averill Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,189,490.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,189,490.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,189,490.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.9 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    00032Q104


    1Names of Reporting Persons

    Cowen Aaron
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,727,510.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,727,510.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,727,510.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Aadi Bioscience, Inc.
    (b)Address of issuer's principal executive offices:

    17383 Sunset Avenue, Suite A250 Pacific Palisades, CA 90272
    Item 2. 
    (a)Name of person filing:

    Suvretta Capital Management, LLC Averill Master Fund, Ltd. Aaron Cowen
    (b)Address or principal business office or, if none, residence:

    Suvretta Capital Management, LLC 540 Madison Avenue, 7th Floor New York, New York 10022 United States of America Averill Master Fund, Ltd. c/o Maples Corporate Services Limited P.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Aaron Cowen c/o Suvretta Capital Management, LLC 540 Madison Avenue, 7th Floor New York, New York 10022
    (c)Citizenship:

    Suvretta Capital Management, LLC - Delaware Averill Master Fund, Ltd. - Cayman Islands Aaron Cowen - United States
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    00032Q104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Items 6 through 9 and 11 of each of the cover pages to this Schedule 13G are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock directly held by Averill Master Fund, Ltd. (the "Fund"), which may be deemed to be indirectly beneficially owned by Suvretta Capital Management, LLC and Aaron Cowen, as well as Common Stock that may be acquired upon the exercise of pre-funded warrants with no expiration date with an exercise price of $0.0001 per share of Common Stock ("Pre-Funded Warrants"), subject to the limitations on exercise described below. The Pre-Funded Warrants are only exercisable to the extent that after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 9.99% of the outstanding Common Stock (the "Maximum Percentage"). By written notice to the Issuer, the Fund may from time to time increase or decrease the Maximum Percentage applicable to it to any other percentage not in excess of 19.99%, provided that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer. As a result of this restriction, the Pre-Funded Warrants are not all presently exercisable and the number of shares of Common Stock that may be issued upon exercise of the Pre-Funded Warrants by the above holders may change depending upon changes in the outstanding Common Stock. Suvretta Capital Management, LLC - 4,727,510 Averill Master Fund, Ltd. - 4,189,490 Aaron Cowen - 4,727,510
    (b)Percent of class:

    Suvretta Capital Management, LLC - 9.99% Averill Master Fund, Ltd. - 8.9% Aaron Cowen - 9.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Suvretta Capital Management, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0

     (ii) Shared power to vote or to direct the vote:

    Suvretta Capital Management, LLC - 4,727,510 Averill Master Fund, Ltd. - 4,189,490 Aaron Cowen - 4,727,510

     (iii) Sole power to dispose or to direct the disposition of:

    Suvretta Capital Management, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Suvretta Capital Management, LLC - 4,727,510 Averill Master Fund, Ltd. - 4,189,490 Aaron Cowen - 4,727,510

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    All of the securities reported in this Schedule 13G are directly owned by advisory clients of Suvretta Capital Management, LLC. None of those advisory clients, other than Averill Master Fund, Ltd., may be deemed to beneficially own more than 5% of the Common Stock, par value $0.0001 per share.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Please see Exhibit B attached hereto.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    SUVRETTA CAPITAL MANAGEMENT, LLC
     
    Signature:By: /s/ Aaron Cowen
    Name/Title:Aaron Cowen / Authorized Signatory
    Date:03/11/2025
     
    Averill Master Fund, Ltd.
     
    Signature:By: /s/ Aaron Cowen
    Name/Title:Aaron Cowen / Director
    Date:03/11/2025
     
    Cowen Aaron
     
    Signature:By: /s/ Aaron Cowen
    Name/Title:AARON COWEN
    Date:03/11/2025

    Comments accompanying signature:  * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
    Exhibit Information

    [Exhibit A - Joint Filing Agreement] [Exhibit B - Control Person Identification]

    Get the next $AADI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AADI

    DatePrice TargetRatingAnalyst
    8/27/2024$5.00 → $1.75Overweight → Neutral
    Piper Sandler
    8/21/2024$11.00 → $1.50Buy → Hold
    Jefferies
    8/21/2024Buy → Hold
    TD Cowen
    12/15/2023Buy → Neutral
    H.C. Wainwright
    1/11/2022$45.00Buy
    Jefferies
    11/24/2021$47.00 → $49.00Buy
    HC Wainwright & Co.
    10/1/2021Outperform
    Cowen & Co.
    9/14/2021$51.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $AADI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update

      MORRISTOWN, N.J., March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience  Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. Contact:[email protected]  View original content to download multimedia:https://w

      3/14/25 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Announces Closing of $100 Million PIPE Financing

      MORRISTOWN, N.J., March 4, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced the closing of its previously announced private placement. The private placement was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han, co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners, for total gross proceeds of approximately $100 million. Aadi sold and issued an aggregate of 21,592

      3/4/25 4:05:00 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders

      MORRISTOWN, N.J., March 3, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced that the Company's stockholders have approved all proposals voted on at the Company's Special Meeting of Stockholders ("Special Meeting") held on February 28, 2025. Approved proposals include: Divestiture Proposal. The approval of the sale by Aadi to KAKEN INVESTMENTS INC. ("Kaken") of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc. ("Aadi Sub") and thereby all or substantially all of Aadi's assets related to its FYARRO® (si

      3/3/25 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Leadership Updates

    Live Leadership Updates

    See more
    • Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer

      Dr. Lennon brings over 20 years of pharmaceutical experience, including deep expertise in the development and commercialization of mTOR inhibitors Leadership transition expected to accelerate growth and leverage ground-breaking nanoparticle technology in FYARRO® to build a leading precision oncology company On track for interim analysis on 40 patients in tumor agnostic PRECISION1 trial in patients with TSC1/TSC2 alterations and trial initiations in endometrial and neuroendocrine cancers before the end of 2023 LOS ANGELES, Oct. 2, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a biopharmaceutical company focused on developing and commercializing precision therapies with mTOR pathwa

      10/2/23 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

      LOS ANGELES, April 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the acceptance of abstracts for poster presentation at the upcoming 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL.  The presentations will consist of a company-sponsored Trials-in-Progress (TIP) update from the PRECISION 1 Phase 2 study and combination data of nab-sirolimus and pazopanib (PAZO) from an ongoing Investigator Initiated Trial.    The details of the poster presentations are below: Title

      4/26/23 4:05:00 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting

      LOS ANGELES, April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of three posters at the 2023 American Association for Cancer Research Annual Meeting (AACR), taking place April 14-19, 2023, in Orlando, FL. The presentations at AACR 2023 include: a trials-in-progress (TIP) poster for the ongoing PRECISION 1 trial, a registrational directed tumor agnostic study for patients with solid tumors driven by TSC1 or TSC2 alterations; results on the anti-tumor activity of nab-s

      4/14/23 1:09:00 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    SEC Filings

    See more
    • SEC Form S-8 filed by Aadi Bioscience Inc.

      S-8 - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

      3/28/25 4:53:43 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

      3/26/25 8:21:16 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Aadi Bioscience, Inc. (0001422142) (Filer)

      3/18/25 4:38:49 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aadi Bioscience downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Aadi Bioscience from Overweight to Neutral and set a new price target of $1.75 from $5.00 previously

      8/27/24 7:14:32 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience downgraded by Jefferies with a new price target

      Jefferies downgraded Aadi Bioscience from Buy to Hold and set a new price target of $1.50 from $11.00 previously

      8/21/24 3:41:58 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience downgraded by TD Cowen

      TD Cowen downgraded Aadi Bioscience from Buy to Hold

      8/21/24 7:18:26 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Financials

    Live finance-specific insights

    See more
    • Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update

      MORRISTOWN, N.J., March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience  Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. Contact:[email protected]  View original content to download multimedia:https://w

      3/14/25 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update

      LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience  Aadi is a precision oncology company focused on the commercialization of FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on Twitter and L

      10/30/24 4:05:00 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update

      FYARRO® sales of $6.2 million for Q2 2024, a 15% quarter over quarter sales growth Interim analysis of two-thirds of fully enrolled PRECISION1 trial planned for Q3 2024 Conference call to be held today at 8:30 am EDT LOS ANGELES, Aug. 7, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. "The second quarter saw quarter over quarter sales growth for FYARRO, as anticipated, and an increase in demand across both new and ex

      8/7/24 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Aadi Bioscience Inc.

      SC 13D/A - Aadi Bioscience, Inc. (0001422142) (Subject)

      10/1/24 5:35:56 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aadi Bioscience Inc.

      SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)

      9/3/24 5:51:01 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aadi Bioscience Inc.

      SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)

      8/28/24 4:42:02 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Dalal Anupam was granted 1,561,000 shares (SEC Form 4)

      4 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      3/5/25 7:51:57 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Castelein Caley was granted 1,666,000 shares (SEC Form 4)

      4 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      3/4/25 7:24:11 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Zhao Baiteng was granted 1,250,000 shares (SEC Form 4)

      4 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      3/4/25 6:14:13 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care